Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Decline in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totalling 2,100 shares, a drop of 86.4% from the July 15th total of 15,400 shares. Based on an average daily trading volume, of 11,900 shares, the days-to-cover ratio is presently 0.2 days.

Bavarian Nordic A/S Trading Up 32.5 %

Bavarian Nordic A/S stock traded up $3.34 during midday trading on Wednesday, reaching $13.61. The company’s stock had a trading volume of 359,270 shares, compared to its average volume of 8,202. The stock has a market cap of $3.19 billion, a PE ratio of 21.60 and a beta of 1.67. Bavarian Nordic A/S has a 52 week low of $5.95 and a 52 week high of $14.24. The business has a 50-day moving average price of $8.61 and a 200-day moving average price of $8.05.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.